2020-07-16
Camurus' Interim Report Second Quarter 2020
”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”
Read the full report on Camurus' website: https://www.camurus.com/financial-reports/
2020-07-16
”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”
Read the full report on Camurus' website: https://www.camurus.com/financial-reports/
2019-04-10
Aimpoint has been awarded a large contract of USD 24 million from the U.S. Military for the FCS13-RE system for SAAB…
Read more2019-04-10
Camurus’ rights issue of 403 MSEK has been oversubscribed. The rights issue was carried out to secure financing of t…
Read more2019-04-10
New positive results from a Phase 3 study show that Camurus’ Buvidal® provides better treatment effect for fentanyl…
Read more2019-04-10
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and…
Read more2019-02-26
Based on Aimpoint's red dot sight for fire arms, the company has developed a commercial VR platform, GAIM, which is…
Read more